首都转化医学创新大赛:医学科技成果转化新纪元

2017-09-21 李晨 科学网

9月20日,首都转化医学创新大赛总决赛暨颁奖典礼在北京举行,代表首都转化医学最高水平的27个项目在总决赛中一决高下

9月20日,首都转化医学创新大赛总决赛暨颁奖典礼在北京举行,代表首都转化医学最高水平的27个项目在总决赛中一决高下。国家卫生计生委科教司司长秦怀金、北京市卫生计生委主任雷海潮、北京市卫生计生委副巡视员郑晋普、国家卫计委国际交流与合作中心主任王健副、北京市卫生计生委科教处处长宋玫、中国技术交易所董事长吴汝川等领导出席并讲话。



国家卫生计生委科教司司长秦怀金首先表达了对27位参赛选手的崇高敬意,对北京市卫计委和中国技术交易所等机构的工作给予了极高评价,认为北京市卫计委和中国技术交易所举办的这次大赛对于推动医学科技成果转化工作具有重要意义,对于高端医疗产品的进口替代以及全民健康具有巨大推动作用。

北京市卫生计生委主任雷海潮对大赛的成功举办给予了充分肯定,认为本次大赛具有六个特点:参赛项目均是面向健康与卫生领域的项目;参赛选手以中青年为主,反映出首都转化医学人才储备的充分;项目均来源于临床一线的重要单位,体现了首都各大医疗机构的强大创新能力;参赛项目大部分均处于转化的中后期阶段,有着良好的转化前景;本次大赛组织高效、活泼多样,效果突出;参赛项目大都体现了多学科的融合,体现了医学发展的新趋势。同时,雷海潮宣布,进入总决赛的26个项目待完成立项程序后即可获得财政专项经费支持。

中国技术交易所董事长吴汝川介绍了中国技术交易所在科技成果转化领域的行业地位、在大健康领域的业务布局及本次大赛中的所做工作。他认为本次大赛显著提升了首都医学科技成果转化的氛围,涌现出了一批优质项目,对于生物医药产业创新发展和首都科技创新建设具有重大意义。

总决赛采取现场路演+评委现场打分的形式进行项目比拼,27个项目依次由10个专业评委和36个大众评委现场亮分,最终共评出一等奖3名、二等奖7名、三等奖17名、最佳创意奖3名、最具投资价值奖3名,同时前期赛程中确定的最佳组织奖3名及优秀组织奖7名也一并揭晓。多位专业评委对项目整体进行了精彩的专业点评。

首都转化医学创新大赛由国家卫计委指导、北京市卫计委组织、中国技术交易所承办、北京昌平科技园发展有限公司协办,并于7月24日正式启动。该大赛以充分挖掘首都优秀医疗创新成果,加速医疗创新项目对接投资、产业等各方资源,推动医学科技成果转化工作的全面开展,促进医学与科技的深度融合,助力首都科创中心建设为目标。

大赛赛程分为初赛、复赛和决赛三个环节。各医院共申报项目400余项,其中300余项目通过院内初赛进入复赛阶段。复赛形式为专家函评,北京市卫计委和中国技术交易所共组织医学专家、财务专家、方法学专家、投资界专家和产业界专家70余人次对各个项目进行了细致的会评工作,最终共有77个项目进入决赛。总决赛中,27个项目进行路演,投资转化专家+专业专家+财务专家共同评审,最终确定获奖名单。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1689883, encodeId=cea116898835f, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Wed Nov 01 03:15:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690328, encodeId=e89f1690328df, content=<a href='/topic/show?id=92a83404183' target=_blank style='color:#2F92EE;'>#医学创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34041, encryptionId=92a83404183, topicName=医学创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3af529038789, createdName=lifestar, createdTime=Fri Aug 17 07:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078734, encodeId=a46020e87342f, content=<a href='/topic/show?id=442458591a3' target=_blank style='color:#2F92EE;'>#新纪元#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58591, encryptionId=442458591a3, topicName=新纪元)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Oct 03 00:15:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285422, encodeId=2ec81285422a9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 23 12:15:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1689883, encodeId=cea116898835f, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Wed Nov 01 03:15:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690328, encodeId=e89f1690328df, content=<a href='/topic/show?id=92a83404183' target=_blank style='color:#2F92EE;'>#医学创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34041, encryptionId=92a83404183, topicName=医学创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3af529038789, createdName=lifestar, createdTime=Fri Aug 17 07:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078734, encodeId=a46020e87342f, content=<a href='/topic/show?id=442458591a3' target=_blank style='color:#2F92EE;'>#新纪元#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58591, encryptionId=442458591a3, topicName=新纪元)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Oct 03 00:15:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285422, encodeId=2ec81285422a9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 23 12:15:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1689883, encodeId=cea116898835f, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Wed Nov 01 03:15:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690328, encodeId=e89f1690328df, content=<a href='/topic/show?id=92a83404183' target=_blank style='color:#2F92EE;'>#医学创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34041, encryptionId=92a83404183, topicName=医学创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3af529038789, createdName=lifestar, createdTime=Fri Aug 17 07:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078734, encodeId=a46020e87342f, content=<a href='/topic/show?id=442458591a3' target=_blank style='color:#2F92EE;'>#新纪元#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58591, encryptionId=442458591a3, topicName=新纪元)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Oct 03 00:15:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285422, encodeId=2ec81285422a9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 23 12:15:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-10-03 zutt
  4. [GetPortalCommentsPageByObjectIdResponse(id=1689883, encodeId=cea116898835f, content=<a href='/topic/show?id=a6fd540305d' target=_blank style='color:#2F92EE;'>#成果转化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54030, encryptionId=a6fd540305d, topicName=成果转化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b5828899049, createdName=ms6323715314570549, createdTime=Wed Nov 01 03:15:00 CST 2017, time=2017-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1690328, encodeId=e89f1690328df, content=<a href='/topic/show?id=92a83404183' target=_blank style='color:#2F92EE;'>#医学创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34041, encryptionId=92a83404183, topicName=医学创新)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3af529038789, createdName=lifestar, createdTime=Fri Aug 17 07:15:00 CST 2018, time=2018-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2078734, encodeId=a46020e87342f, content=<a href='/topic/show?id=442458591a3' target=_blank style='color:#2F92EE;'>#新纪元#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58591, encryptionId=442458591a3, topicName=新纪元)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Oct 03 00:15:00 CST 2017, time=2017-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285422, encodeId=2ec81285422a9, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sat Sep 23 12:15:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]

相关资讯

SCIENCE:干细胞疗法证实安全

人类首次来自诱导多能干细胞(IPS,Induced Pluripotent Stem Cells)分化的上皮细胞的临床试验终于出成果啦!

从实验室到临床:转化医学推动肿瘤免疫治疗迈入 2.0 时代

要说近些年肿瘤治疗领域最受关注和值得期待的研究突破,免疫治疗可谓当仁不让。

32家医院入选国家临床医学研究中心,还有哪些专科未布局

昨日(7月22日)科技部、国家卫生计生委、中央军委后勤保障部和国家食品药品监督管理总局在京联合召开国家临床医学研究中心建设工作推进会,发布了《国家临床医学研究中心五年(2017-2022年)发展规划》、《国家临床医学研究中心管理办法(2017年修订)》和《国家临床医学研究中心运行绩效评估方案》3份文件。

癌症检测笔:96%**率,再也不用担心手术“多切”或“漏切”了

近日,德克萨斯大学的研究人员研发出了一种癌症检测笔,可以在十秒之内检测出癌症组织。研究人员称,这项技术可以让癌症手术变得更加精确和安全。